tetano
Editor, Senior Moderator
Aging (Albany NY)
. 2020 Aug 14;12.
doi: 10.18632/aging.103770. Online ahead of print.
Elevated Lactate Dehydrogenase (LDH) level as an independent risk factor for the severity and mortality of COVID-19
Chang Li[SUP] 1 [/SUP], Jianfang Ye[SUP] 2 3 [/SUP], Qijian Chen[SUP] 4 [/SUP], Weihua Hu[SUP] 5 [/SUP], Lingling Wang[SUP] 2 3 [/SUP], Yameng Fan[SUP] 6 [/SUP], Zhanjin Lu[SUP] 2 3 [/SUP], Jie Chen[SUP] 7 [/SUP], Zaishu Chen[SUP] 8 [/SUP], Shiyan Chen[SUP] 2 3 [/SUP], Junlu Tong[SUP] 2 3 [/SUP], Wei Xiao[SUP] 1 [/SUP], Jin Mei[SUP] 9 [/SUP], Hongyun Lu[SUP] 10 [/SUP]
Affiliations
Abstract
Early identification of severe patients with coronavirus disease 2019 (COVID-19) is very important for individual treatment. We included 203 patients with COVID-19 by propensity score matching in this retrospective, case-control study. The effects of serum lactate dehydrogenase (LDH) at admission on patients with COVID-19 were evaluated. We found that serum LDH levels had a 58.7% sensitivity and 82.0% specificity, based on a best cut-off of 277.00 U/L, for predicting severe COVID-19. And a cut-off of 359.50 U/L of the serum LDH levels resulted in a 93.8% sensitivity, 88.2% specificity for predicting death of COVID-19. Additionally, logistic regression analysis and Cox proportional hazards model respectively indicated that elevated LDH level was an independent risk factor for the severity (HR: 2.73, 95% CI: 1.25-5.97; P=0.012) and mortality (HR: 40.50, 95% CI: 3.65-449.28; P=0.003) of COVID-19. Therefore, elevated LDH level at admission is an independent risk factor for the severity and mortality of COVID-19. LDH can assist in the early evaluating of COVID-19. Clinicians should pay attention to the serum LDH level at admission for patients with COVID-19.
Keywords: COVID-19; lactate dehydrogenase; mortality; risk factor; severity.
. 2020 Aug 14;12.
doi: 10.18632/aging.103770. Online ahead of print.
Elevated Lactate Dehydrogenase (LDH) level as an independent risk factor for the severity and mortality of COVID-19
Chang Li[SUP] 1 [/SUP], Jianfang Ye[SUP] 2 3 [/SUP], Qijian Chen[SUP] 4 [/SUP], Weihua Hu[SUP] 5 [/SUP], Lingling Wang[SUP] 2 3 [/SUP], Yameng Fan[SUP] 6 [/SUP], Zhanjin Lu[SUP] 2 3 [/SUP], Jie Chen[SUP] 7 [/SUP], Zaishu Chen[SUP] 8 [/SUP], Shiyan Chen[SUP] 2 3 [/SUP], Junlu Tong[SUP] 2 3 [/SUP], Wei Xiao[SUP] 1 [/SUP], Jin Mei[SUP] 9 [/SUP], Hongyun Lu[SUP] 10 [/SUP]
Affiliations
- PMID: 32805722
- DOI: 10.18632/aging.103770
Abstract
Early identification of severe patients with coronavirus disease 2019 (COVID-19) is very important for individual treatment. We included 203 patients with COVID-19 by propensity score matching in this retrospective, case-control study. The effects of serum lactate dehydrogenase (LDH) at admission on patients with COVID-19 were evaluated. We found that serum LDH levels had a 58.7% sensitivity and 82.0% specificity, based on a best cut-off of 277.00 U/L, for predicting severe COVID-19. And a cut-off of 359.50 U/L of the serum LDH levels resulted in a 93.8% sensitivity, 88.2% specificity for predicting death of COVID-19. Additionally, logistic regression analysis and Cox proportional hazards model respectively indicated that elevated LDH level was an independent risk factor for the severity (HR: 2.73, 95% CI: 1.25-5.97; P=0.012) and mortality (HR: 40.50, 95% CI: 3.65-449.28; P=0.003) of COVID-19. Therefore, elevated LDH level at admission is an independent risk factor for the severity and mortality of COVID-19. LDH can assist in the early evaluating of COVID-19. Clinicians should pay attention to the serum LDH level at admission for patients with COVID-19.
Keywords: COVID-19; lactate dehydrogenase; mortality; risk factor; severity.